New strategies for the treatment of acute venous thromboembolism

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 8, 2006, Pages 787-792

  Prandoni, Paolo ^a,c   Lensing, Anthonie W A ^b   Pesavento, Raffaele ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Anticoagulation; Deep vein thrombosis; Elastic stockings; Heparin; Pulmonary embolism; Thrombophilia; Venous thromboembolism; Warfarin

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 5 LEIDEN; DABIGATRAN ETEXILATE; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; PROTEIN C; PROTEIN S; PROTHROMBIN; REVIPARIN; THROMBIN INHIBITOR; TINZAPARIN; WARFARIN; XIMELAGATRAN;

AUTOIMMUNE THROMBOCYTOPENIA; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CANCER PATIENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HEART RIGHT VENTRICLE FAILURE; HUMAN; LONG TERM CARE; LUNG EMBOLISM; PRIORITY JOURNAL; PROTECTIVE CLOTHING; REVIEW; SECONDARY PREVENTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; DRUGS, INVESTIGATIONAL; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; NEOPLASMS; PULMONARY EMBOLISM; STOCKINGS, COMPRESSION; THROMBIN; THROMBOEMBOLISM; TIME FACTORS; VENOUS THROMBOSIS; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 33845640981     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-955461     Document Type: Review

References (36)

1. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:401S-428S
2. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin. Chest 2004;26:188S-203S
3. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-687
4. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996;334:677-681
5. Wells PS, Anderson DR, Rodger MA, et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med 2005;165:733-738
6. Brandjes DPM, Büller HR, Heijboer H, Huisman MV, de Rijk M, Jagt H. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997;349:759-762
7. Prandoni P, Lensing AWA, Prins MH, et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome. A randomized, controlled trial. Ann Intern Med 2004;141:249-256
8. Hutten B, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-3083
9. Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000;84:805-810
10. Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488
11. Lee AY, Levine MN, Baker RI, et al. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153
12. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch Intern Med 2002;162:1729-1735
13. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-662
14. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997;337:663-669
15. Quinlan DJ, Mcquillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a metaanalysis of randomized, controlled trials. Ann Intern Med 2004;140:175-183
16. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353:1386-1389
17. Grifoni S, Olivotto I, Cecchini P, et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 2000;101:2817-2822
18. Konstantinides S, Gebel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002;347:1143-1150
19. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7
20. Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997;82:423-428
21. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis. Incidence and risk factors. Arch Intern Med 2000;160:769-774
22. Heit JA, Mohr N, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ III. Predictors of recurrence after deep vein thrombosis and pulmonary embolism. A population-based cohort study. Arch Intern Med 2000;160:761-768
23. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661-1665
24. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-907
25. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001;345:165-169
26. Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003;139:19-25
27. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425-1434
28. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:631-639
29. Prandoni P, Lensing AWA, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002;137:985-990
30. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006;355:1780-1789
31. The Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349:1695-1702
32. B̈ller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. Ann Intern Med 2004;140:867-873
33. Prandoni P. Toward the simplification of antithrombotic treatment of venous thromboembolism. Ann Intern Med 2004;140:925-926
34. The Persist Investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. J Thromb Haemost 2004;2:47-53
35. Fiessinger JN, Huisman MV, Davidson BL, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005;293:681-689
36. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-1721